ArticleGastrointestinal endoscopy2026
Anatomical location of colorectal neoplasia in patients with positive stool test (multitarget stool deoxyribonucleic acid or fecal immunochemical test) results: data from the New Hampshire Colonoscopy Registry.
Article in Gastrointestinal endoscopy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
BACKGROUND AND
aimsData comparing the location of polyp yield in patients with positive stool test results can aid screening test selection. We conducted a cross-sectional analysis of New Hampshire Colonoscopy Registry data to compare the location, left versus right side of the colon, of neoplasia detected on colonoscopy after a multitarget stool DNA (mt-sDNA) test or a fecal immunochemical test (FIT), compared with a reference group undergoing colonoscopy without a stool test.
methodsOur outcomes were advanced lesions (adenomas and/or serrated polyps, including cancer), advanced adenomas, or advanced serrated polyps stratified by location. We examined the prevalence of left- versus right-sided lesions across 3 cohorts.
resultsAs compared to colonoscopy (n = 68,645), both FIT+ (n = 584) and mt-sDNA+ (n = 1176) patients had higher proportions of advanced lesions and advanced adenomas on both sides of the colon (P < .001). Mt-sDNA+ patients had significantly higher risks for right-sided advanced serrated polyps (odds ratio [OR], 3.21; 95% confidence interval [CI], 2.67-3.85; colonoscopy [reference]) and right-sided advanced lesions (OR, 3.13; 95% CI, 2.66-3.68; colonoscopy [reference]) as compared to FIT+ (advanced serrated polyps: OR, 1.38; 95% CI, 0.99-1.99 and advanced lesions: OR, 1.84; 95% CI, 1.43-2.37) or colonoscopy (reference). In our main analysis, the colonoscopy-only group had significantly higher odds of each outcome on the right side than the left side; in comparison, the odds for FIT+ and mt-sDNA+ patients were more evenly distributed throughout the colon.
conclusionsOur data suggest that FIT+ tests are associated with higher detection of both right- and left-sided advanced adenomas as compared to colonoscopy without a prior stool test. Furthermore, mt-sDNA+ patients had higher proportions of left- and right-sided advanced adenomas and advanced serrated polyps, particularly on the right side.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.